Skip to content

To Compare Proton and Photon Radiotherapy in Adults with Primary Brain Tumors

Proton versus Photon Radiotherapy In Adults with primary brain tumors Evaluating functional survival A Phase 3 Randomized Controlled Trial - PRIDE

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/082568
Enrollment
156
Registered
2025-03-18
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G94- Other disorders of brain in diseases classified elsewhere Health Condition 2: G938- Other specified disorders of brain

Interventions

Intervention1: photon therapy: Proton beam therapy (experimental arm) is superior in functional preservation compared to photon therapy (standard arm) in adults with primary brain tumors receiving foc

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Primary brain tumors 2. Age at irradiation 18 to 70 years 3. Karnofsky Performance Status more than 60 4. Diagnosis histopathological radiological of primary brain tumor with an expected survival of above 5 years 5. Planned for focal cranial radiotherapy 6. Informed consent taken

Exclusion criteria

Exclusion criteria: 1. Reirradiation 2. Palliative radiotherapy 3. Multifocal or multicentric disease 4. Planned for whole brain irradiation or craniospinal irradiation 5. Planned for hypofractionated or stereotactic radiotherapy

Design outcomes

Primary

MeasureTime frame
Primary endpoint The 5 year rate of overall survival without functional deterioration functional survival equal to fS will be calculated from the date of randomization. An event concerning the primary endpoint will include Neurocognitive decline CTCAE grade 2 ototoxicity New neuroendocrine axis dysfunction or worsening of pre existing dysfunction Neurological and functional impairment CTCAE gr 3 radionecrosis Disease progression All cause mortalityTimepoint: 5 years

Secondary

MeasureTime frame
Secondary endpoints: 1. Overall survival & Progression-free survival. 2. Radiation-induced early toxicity. 3. Cumulative incidence of sub-domains of functional survival. 4. Quality of Life (patient-reported outcomes) 5. Post hoc analysis per stratification factorsTimepoint: At the completion of the study

Countries

India

Contacts

Public ContactDr ARCHYA DASGUPTA

Tata Memorial Hospital

archya1010@gmail.com022241760176020

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 15, 2026